CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 97 filers reported holding CYTOMX THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $1,122,000 | -30.4% | 104,365 | -2.2% | 0.06% | -33.3% |
| Q4 2018 | $1,611,000 | -7.0% | 106,720 | +13.9% | 0.09% | +32.4% |
| Q3 2018 | $1,733,000 | -24.1% | 93,662 | -6.2% | 0.07% | -24.4% |
| Q2 2018 | $2,284,000 | +5.1% | 99,904 | +26.2% | 0.09% | +2.3% |
| Q1 2018 | $2,174,000 | +78.6% | 79,143 | +37.3% | 0.09% | +60.0% |
| Q4 2017 | $1,217,000 | -21.7% | 57,643 | -32.6% | 0.06% | -34.5% |
| Q3 2017 | $1,554,000 | +20.2% | 85,539 | +2.6% | 0.08% | -21.5% |
| Q2 2017 | $1,293,000 | -1.4% | 83,392 | +9.8% | 0.11% | -17.7% |
| Q1 2017 | $1,311,000 | +88.6% | 75,924 | +20.0% | 0.13% | +54.8% |
| Q4 2016 | $695,000 | -34.2% | 63,272 | -6.1% | 0.08% | -40.0% |
| Q3 2016 | $1,057,000 | +52.7% | 67,396 | -0.5% | 0.14% | +44.3% |
| Q2 2016 | $692,000 | -27.3% | 67,721 | -8.3% | 0.10% | +64.4% |
| Q1 2016 | $952,000 | +18.4% | 73,830 | +91.8% | 0.06% | -42.2% |
| Q4 2015 | $804,000 | – | 38,502 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,500,000 | $7,635,000 | 1.78% |
| Altium Capital Management LP | 1,233,642 | $6,279,000 | 1.65% |
| RA Capital Management | 3,500,000 | $17,815,000 | 0.25% |
| Soleus Capital Management, L.P. | 261,050 | $1,329,000 | 0.21% |
| Affinity Asset Advisors, LLC | 125,000 | $636,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,078,103 | $5,488,000 | 0.16% |
| Point72 Asset Management, L.P. | 6,303,025 | $32,082,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 249,146 | $1,268,000 | 0.13% |
| Candriam S.C.A. | 3,305,940 | $16,826,000 | 0.11% |
| RTW INVESTMENTS, LP | 1,400,939 | $7,131,000 | 0.11% |